| Dr William Franklin Sherman Jr, MD | |
|
7301 Hennessy Blvd., Suite 200, Baton Rouge, LA 70808 | |
| (225) 766-0050 | |
| (225) 766-1499 |
| Full Name | Dr William Franklin Sherman Jr |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 19 Years |
| Location | 7301 Hennessy Blvd., Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508037516 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | PGY.2-LSUNO (Louisiana) | Secondary |
| 207X00000X | Orthopaedic Surgery | 201532 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tulane Medical Center | New orleans, LA | Hospital |
| Omega Hospital, Llc | Metairie, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Administrators Of The Tulane Educational Fund | 0446163760 | 369 |
News Archive
LEAD Therapeutics, a privately held drug discovery company, announced the discovery of a novel antibiotic with potent activity against many of the most common antibiotic resistant bacteria.
Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced its financial results for the second quarter ended June 30, 2009.
A study conducted at the Spanish Centre for Pharmacoepidemiological Research revealed that the risk of gastrointestinal complications due to nonsteroidal anti-inflammatory drug (NSAID) use varies by specific NSAID administered and by dosage. The study further determined that NSAIDs with a long half-life or slow-release formulation are associated with a greater risk of GI bleeding or perforation.
Precision BioSciences and Agrivida revealed today that they have entered into a trait development collaboration based on precise gene modifications made possible by Precision's Directed Nuclease Editor (DNE) Technology.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that the paper "An alpha-2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine Lowering Effects and Therapeutic Response of the Beta Blocker Bucindolol in Chronic Heart Failure" was published in the January 2010 edition of the peer-reviewed journal Circulation: Heart Failure (http://circheartfailure.ahajournals.org).
› Verified 2 days ago
| Entity Name | Administrators Of The Tulane Educational Fund |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528014164 PECOS PAC ID: 0446163760 Enrollment ID: O20031201000636 |
News Archive
LEAD Therapeutics, a privately held drug discovery company, announced the discovery of a novel antibiotic with potent activity against many of the most common antibiotic resistant bacteria.
Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced its financial results for the second quarter ended June 30, 2009.
A study conducted at the Spanish Centre for Pharmacoepidemiological Research revealed that the risk of gastrointestinal complications due to nonsteroidal anti-inflammatory drug (NSAID) use varies by specific NSAID administered and by dosage. The study further determined that NSAIDs with a long half-life or slow-release formulation are associated with a greater risk of GI bleeding or perforation.
Precision BioSciences and Agrivida revealed today that they have entered into a trait development collaboration based on precise gene modifications made possible by Precision's Directed Nuclease Editor (DNE) Technology.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that the paper "An alpha-2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine Lowering Effects and Therapeutic Response of the Beta Blocker Bucindolol in Chronic Heart Failure" was published in the January 2010 edition of the peer-reviewed journal Circulation: Heart Failure (http://circheartfailure.ahajournals.org).
› Verified 2 days ago
| Entity Name | Louisiana State University School Of Medicine In New Orleans Faculty G |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477582526 PECOS PAC ID: 0244136448 Enrollment ID: O20031209000661 |
News Archive
LEAD Therapeutics, a privately held drug discovery company, announced the discovery of a novel antibiotic with potent activity against many of the most common antibiotic resistant bacteria.
Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced its financial results for the second quarter ended June 30, 2009.
A study conducted at the Spanish Centre for Pharmacoepidemiological Research revealed that the risk of gastrointestinal complications due to nonsteroidal anti-inflammatory drug (NSAID) use varies by specific NSAID administered and by dosage. The study further determined that NSAIDs with a long half-life or slow-release formulation are associated with a greater risk of GI bleeding or perforation.
Precision BioSciences and Agrivida revealed today that they have entered into a trait development collaboration based on precise gene modifications made possible by Precision's Directed Nuclease Editor (DNE) Technology.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that the paper "An alpha-2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine Lowering Effects and Therapeutic Response of the Beta Blocker Bucindolol in Chronic Heart Failure" was published in the January 2010 edition of the peer-reviewed journal Circulation: Heart Failure (http://circheartfailure.ahajournals.org).
› Verified 2 days ago
| Entity Name | Orthopedic Center For Sports Medicine And Reconstructive Surgery |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124171673 PECOS PAC ID: 4082685250 Enrollment ID: O20040802001383 |
News Archive
LEAD Therapeutics, a privately held drug discovery company, announced the discovery of a novel antibiotic with potent activity against many of the most common antibiotic resistant bacteria.
Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced its financial results for the second quarter ended June 30, 2009.
A study conducted at the Spanish Centre for Pharmacoepidemiological Research revealed that the risk of gastrointestinal complications due to nonsteroidal anti-inflammatory drug (NSAID) use varies by specific NSAID administered and by dosage. The study further determined that NSAIDs with a long half-life or slow-release formulation are associated with a greater risk of GI bleeding or perforation.
Precision BioSciences and Agrivida revealed today that they have entered into a trait development collaboration based on precise gene modifications made possible by Precision's Directed Nuclease Editor (DNE) Technology.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that the paper "An alpha-2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine Lowering Effects and Therapeutic Response of the Beta Blocker Bucindolol in Chronic Heart Failure" was published in the January 2010 edition of the peer-reviewed journal Circulation: Heart Failure (http://circheartfailure.ahajournals.org).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William Franklin Sherman Jr, MD Po Box 98035, Baton Rouge, LA 70898 Ph: (225) 766-0050 | Dr William Franklin Sherman Jr, MD 7301 Hennessy Blvd., Suite 200, Baton Rouge, LA 70808 Ph: (225) 766-0050 |
News Archive
LEAD Therapeutics, a privately held drug discovery company, announced the discovery of a novel antibiotic with potent activity against many of the most common antibiotic resistant bacteria.
Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced its financial results for the second quarter ended June 30, 2009.
A study conducted at the Spanish Centre for Pharmacoepidemiological Research revealed that the risk of gastrointestinal complications due to nonsteroidal anti-inflammatory drug (NSAID) use varies by specific NSAID administered and by dosage. The study further determined that NSAIDs with a long half-life or slow-release formulation are associated with a greater risk of GI bleeding or perforation.
Precision BioSciences and Agrivida revealed today that they have entered into a trait development collaboration based on precise gene modifications made possible by Precision's Directed Nuclease Editor (DNE) Technology.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that the paper "An alpha-2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine Lowering Effects and Therapeutic Response of the Beta Blocker Bucindolol in Chronic Heart Failure" was published in the January 2010 edition of the peer-reviewed journal Circulation: Heart Failure (http://circheartfailure.ahajournals.org).
› Verified 2 days ago
Kenneth C. Cranor, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 5408 Flanders Dr, Baton Rouge, LA 70808 Phone: 225-769-0173 Fax: 225-769-1730 | |
Dr. Michael R Robichaux Jr., MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8080 Bluebonnet Blvd, Suite 1000, Baton Rouge, LA 70810 Phone: 225-924-2424 Fax: 225-408-7984 | |
Dr. Barry Michael Rills, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 8080 Bluebonnet Blvd, Suite 1000, Baton Rouge, LA 70810 Phone: 225-924-2424 Fax: 225-408-7984 | |
Dr. John Marshall Whatley, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8080 Bluebonnet Blvd Ste 1000, Baton Rouge, LA 70810 Phone: 225-924-2424 Fax: 225-408-7980 | |
John F Loupe, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 2223 Quail Run Ste G, Baton Rouge, LA 70808 Phone: 225-406-7222 Fax: 225-286-2964 | |
Tabitha Lynn Franklin, CST/CSFA Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 8080 Bluebonnet Blvd Ste 1000, Baton Rouge, LA 70810 Phone: 225-408-6633 Fax: 225-408-7965 | |
Timothy Charles Bowlin, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8080 Bluebonnet Blvd, Suite 1000, Baton Rouge, LA 70810 Phone: 225-924-2424 Fax: 225-408-7980 |